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A B S T R A C T
Advances in technology have allowed for the sensitive, specific, and simultaneous quantitative profiling of
steroid precursors, bioactive steroids and inactive metabolites, facilitating comprehensive characterization of the
serum and urine steroid metabolomes. The quantification of steroid panels is therefore gaining favor over
quantification of single marker metabolites in the clinical and research laboratories. However, although the
biochemical pathways for the biosynthesis and metabolism of steroid hormones are now well defined, a gulf still
exists between this knowledge and its application to the measured steroid profiles. In this review, we present an
overview of steroid hormone biosynthesis and metabolism by the liver and peripheral tissues, specifically
highlighting the pathways linking and differentiating the serum and urine steroid metabolomes. A brief overview
of the methodology used in steroid profiling is also provided.
1. Introduction
Steroid hormones play an essential role in regulating water and salt
balance, metabolism and stress response, and in initiating and main-
taining sexual differentiation and reproduction. Researchers in-
vestigating steroid-related endocrine conditions have measured altera-
tions in the steroid metabolome for several decades. While clinical
laboratories have traditionally measured changes in individual diag-
nostic marker steroids, the quantification of steroid panels are now
gaining widespread traction due to advances in technology, further
driven by the emerging diagnostic power of steroid metabolomics, i.e.
the combination of mass spectrometry-based steroid profiling with
unbiased data analysis by machine learning approaches.
In most cases, alterations in steroid profiles associated with endo-
crine disorders were identified long before the responsible enzymes
were identified or characterized following the advent of modern mo-
lecular techniques. While the biochemical pathways for the biosynth-
esis and metabolism of steroid hormones are now mostly well defined, a
gulf still exists with regard to the application of this knowledge to the
interpretation of the measured multi-steroid profiles in serum and
urine. Researchers and clinicians are increasingly dependent on results
obtained by steroid metabolome analysis, but are often unfamiliar with
the metabolic pathways resulting in the observed steroid profile and the
distinct metabolic pathways explaining the differences between serum
and urine steroid metabolomes.
Therefore, it is the aim of this review to provide a comprehensive
and up-to-date examination of our current knowledge of metabolic
pathways underlying the serum and urine steroid metabolomes. We
briefly review the origins of steroid hormones, and present the resulting
serum metabolome of each of the main classes of steroids. Downstream
metabolism of each of these steroid classes are subsequently presented
and linked to the resulting urine steroid excretion patterns. Taken to-
gether this review provides a biochemical overview of the biosynthesis,
metabolism and excretion of steroid hormones.
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2. Origins of steroid hormones
2.1. Overview of de novo steroidogenesis
Steroid hormones are produced through de novo steroidogenesis in
the adrenal cortex, the gonads and the placenta. In addition, a range of
neurosteroids are produced in the brain [1], however these are beyond
the scope of this review. Steroidogenic tissues are unique in their ability
to utilize cholesterol as starting material for the mitochondrial bio-
synthesis of pregnenolone, the precursor steroid in the biosynthesis of
all steroid hormones. Cholesterol can be obtained from multiple sources
including de novo biosynthesis from acetate in the endoplasmic re-
ticulum (ER) [2–4], the hydrolysis of cholesteryl esters stored in lipid
droplets by cholesteryl ester hydrolases, exogenous lipoprotein-derived
cholesterol esters from LDL receptor-mediated endocytic and/or SR-BI-
mediated uptake pathways, and free cholesterol residing in the plasma
membrane [5–8]. All three primary steroidogenic organs, namely the
adrenal cortex, gonads and placenta, can biosynthesize cholesterol de
novo under the regulation of tropic hormones and plasma lipoproteins
are widely accepted as the principal source of cholesterol used for
steroid biosynthesis [5–8].
2.2. Overview of steroidogenic enzymes
Two major functional classes of enzymes are involved in the bio-
synthesis of all steroid hormones, namely the cytochrome P450 (CYP)
and hydroxysteroid dehydrogenase (HSD) enzymes. The heme-con-
taining CYP enzymes activate molecular oxygen utilizing NADPH as an
electron donor. During catalysis, they incorporate one oxygen atom into
the substrate while the other oxygen atom is reduced to water. This
catalytic potential allows CYPs to catalyze a wide range of reactions,
with hydroxylation and CeC bond cleavage being relevant reactions in
steroidogenesis [9,10]. CYP enzymes involved in steroidogenesis can be
divided into two groups based on their intracellular location and mode
of electron transfer. CYP type I enzymes are located within the inner
mitochondrial membrane and are dependent on ferredoxin and ferre-
doxin reductase for the delivery of their electrons from NADPH. Fer-
redoxin reductase is a flavoprotein that oxidizes NADPH and transfers
electrons to ferredoxin, a small iron-sulfur protein, which acts as a
mobile electron carrier, delivering the electrons to the CYP. The
adrenally located ferredoxin reductase and ferredoxin are often also
referred to as adrenodoxin reductase (AdxR) and adrenodoxin (Adx),
respectively. CYP type II enzymes are found in the ER and are depen-
dent on the electron donor enzyme cytochrome P450 oxidoreductase
(POR) for electron delivery. POR contains a flavin adenine dinucleotide
(FAD) and a flavin mononucleotide (FMN) allowing the enzyme to
oxidize NADPH and reduce the CYP enzyme in a stepwise manner. The
availability of NADPH is a vital aspect of CYP-catalyzed reactions, with
redox partner ratios differentially influencing CYP activities [11–13].
The other main functional class of enzymes involved in ster-
oidogenesis are the HSD enzymes which are dependent on NAD(P)H
and NAD(P)+ co-factors. HSDs are subdivided into two distinct enzyme
superfamilies based on their structural fold. These are the short chain
dehydrogenases and aldo-keto reductases (AKR). The function of the
HSD enzymes from both families is to catalyze the conversion of a given
hydroxysteroid to its corresponding ketosteroid counterpart and vice
versa, and in doing so, regulate the activity of the steroid at specific
steroid receptors [14]. Most HSD-catalyzed reactions are mechan-
istically reversible and can function bi-directionally, although a pro-
minent directionality is observed in vivo as a result of co-factor affinity
and cellular redox status. An exception to this rule are the two HSD3B
isoforms, HSD3B1 and HSD3B2, which catalyze an irreversible reaction,
directly linked to the isomerization of the Δ5 double bond. These en-
zymes have dual catalytic activity and not only transform the hydroxy
group on carbon 3 to a keto group but additionally isomerize the double
bond from Δ5 to Δ4 [15–18].
2.3. Overview of adrenal steroidogenesis
The cortex of the adrenal gland is responsible for the biosynthesis of
mineralocorticoids and glucocorticoids, as well as the production of
adrenal androgen precursors and androgens, a function unique to
higher primates [19,20]. The cortex is subdivided into three functional
zones, each responsible for the production of a distinct steroid class due
to the zone-specific expression of steroidogenic enzymes. The outer
zone of the adrenal is termed the zona glomerulosa and expresses en-
zymes that catalyze the production of the major mineralocorticoid al-
dosterone under the control of the renin-angiotensin-aldosterone
system. The middle zone, the zona fasciculata, is responsible for the
production of the primary glucocorticoid, cortisol. Finally, the inner-
most zone, the zona reticularis, contributes to the formation of C19 an-
drogen precursors including dehydroepiandrosterone (DHEA) and its
sulfate (DHEAS), androstenedione (A4) and 11β-hydro-
xyandrostenedione (11OHA4) (Fig. 1). The hypothalamic-pituitary-
adrenal (HPA) axis regulates the production of glucocorticoids and
adrenal androgen precursors by the adrenal. In short, the hypothalamus
produces corticotropin-releasing hormone (CRH) that stimulates corti-
cotrope cells in the anterior pituitary to biosynthesize and release
adrenocorticotropic hormone (ACTH) that in turn stimulates the
adrenal gland to produce steroid hormones, specifically DHEA and
cortisol [21,22]. Glucocorticoids complete the system by having a ne-
gative feedback effect on the pituitary, hypothalamus and the hippo-
campus, inhibiting further stimulation of the adrenal gland, while there
is no feedback inhibition of the HPA axis by adrenal androgen pre-
cursors.
2.4. Overview of gonadal steroidogenesis
Steroidogenesis in the gonads is tailored to the production of an-
drogens and estrogens, with the corpus luteum additionally playing an
important role in the production of the major endogenous progestogen,
progesterone. Similar to the zonation of the adrenal, it is the cell-spe-
cific expression pattern of steroidogenic enzymes within each cell type
that dictates steroid output (Fig. 2). Gonadal steroidogenesis is initiated
by the development of the hypothalamic-pituitary-gonadal axis at
puberty. The hypothalamus produces and secretes gonadotropin-re-
leasing hormone (GnRH) in a pulsatile fashion, which in turn stimulates
the production and secretion of luteinizing hormone (LH) from the pi-
tuitary. Androgens and estrogens provide negative feedback at the
hypothalamus and pituitary level to suppress LH in men and women,
respectively [23]. Gonadal steroidogenesis is also active during ‘mini-
puberty’, a short period of hypothalamic-pituitary-gonadal axis acti-
vation during the neonatal period [24].
2.5. Biosynthesis of specific steroid classes
2.5.1. Mineralocorticoid production in the adrenal zona glomerulosa
Enzyme expression in the zona glomerulosa is tailored to produce the
C21 mineralocorticoid, aldosterone. CYP11A1 converts cholesterol to
pregnenolone, followed by the HSD3B2-catalyzed conversion of preg-
nenolone to the Δ4 steroid, progesterone. HSD3B2 is present in both the
mitochondria and ER of zona glomerulosa cells [25,26]. Progesterone is
subsequently converted to 11-deoxycorticosterone (DOC) by CYP21A2,
which is abundantly expressed in the ER of the zona glomerulosa
[26,27]. The lack of CYP17A1 expression in the zona glomerulosa [25]
together with the abundant expression of HSD3B2 ensures that all
steroid intermediates are directed towards aldosterone biosynthesis.
Two isoforms of CYP11B are expressed in the zona glomerulosa, both
with the ability to catalyze the 11β-hydroxylation of DOC yielding
corticosterone. CYP11B2, which is also known as aldosterone synthase,
additionally exhibits 18-hydroxylase and 18-methyl oxidase activity,
which are required to convert corticosterone to aldosterone via the 18-
hydroxycorticosterone intermediate [26,28,29].
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2.5.2. Glucocorticoid production in the adrenal zona fasciculata
The adrenal zona fasciculata is the site of glucocorticoid production.
Pregnenolone, produced from the CYP11A1 catalyzed side-chain clea-
vage of cholesterol, is converted to 17α-hydroxyprogesterone (17OHP),
the universal precursor of cortisol production, by HSD3B2 and
CYP17A1 17α-hydroxylase activity. CYP21A2 subsequently catalyzes
the conversion of 17OHP to 11-deoxycortisol, an obligatory step in the
production of glucocorticoids. Finally, CYP11B1, located in the mi-
tochondria of the zona fasciculata cells, facilitates the final step in
glucocorticoid biosynthesis by catalyzing the conversion of 11-deox-
ycortisol to cortisol.
2.5.3. Androgen biosynthesis
2.5.3.1. The classic androgen biosynthesis pathway in the adrenal zona
reticularis and the gonads. Androgen precursors and active androgens
are produced by both the adult adrenal and gonads by the Δ5 pathway
from pregnenolone to DHEA (Fig. 3). This pathway is also referred to as
the ‘classic androgen biosynthesis pathway’. The CYP17A1-catalyzed
17α-hydroxylation of pregnenolone yields 17α-hydroxypregnenolone,
which serves as the preferred substrate for the 17,20-lyase activity of
CYP17A1, producing C19 steroids from C21 precursors [30–32]. It
should be noted that the 17,20-lyase activity of CYP17A1 is
dependent on augmentation by cytochrome b5 (CYB5A) in addition to
electron transfer from POR [33].
The Δ5 pathway is active in the zona reticularis of the adrenal cortex,
which only develops during adrenarche between the ages of 6–10, a
process unique to humans and higher primates. During that time, the
development of a distinct zona reticularis is accompanied by an extreme
increase in the adrenal androgen precursor production due to the de-
creased expression of HSD3B2 in conjunction with increased CYB5A
expression [34–38]. Some of the resulting DHEA is converted to an-
drostenediol by AKR1C3, which exhibits minor expression in the zona
reticularis [39]. However, the majority of DHEA is efficiently sulfated by
the major DHEA sulfotransferase (SULT2A1), which is abundantly ex-
pressed in the zona reticularis [40]. This results in significant DHEAS
output and accounts for DHEAS being the most abundant steroid in
circulation (Table 2) [39,41]. Other Δ5 steroids, e.g. pregnenolone, 17α-
hydroxypregnenolone and androstenediol, can also be released in their
respective sulfated form [42–44]. Moreover, DHEA and androstenediol
can all be converted to their corresponding Δ4 products by the low levels
of HSD3B2, yielding A4 and testosterone, respectively. A4 can serve as an
additional substrate for AKR1C3, yielding testosterone [45]. An age-
Fig. 1. Schematic overview of adrenal steroidogenesis and peripheral modulation of steroid bioactivity. Arrows are labelled with the catalyzing enzyme and
isoform where appropriate. Essential accessory proteins are also indicated: cytochrome b5 (b5); cytochrome P450 oxidoreductase (POR); ferredoxin (FDX); ferredoxin
reductase (FDXR); hexose-6-phosphate dehydrogenase (H6PDH); PAPS synthase 2 (PAPSS2); steroidogenic acute regulatory protein (StAR).
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related gradual decrease in adrenal androgen secretion and excretion,
known as adrenopause, occurs starting in the fourth decade of life and is
associated with a decrease in the zona reticularis cell layer and cell
function. This reaches a minimum by the age of 70, with only about
5–10% of the peak levels observed in young adulthood [46].
Like in the zona reticularis, the Leydig cells of the testes follow the Δ5
pathway due to the co-expression of CYP17A1 and CYB5A (Fig. 2).
However, in the Leydig cells subsequent metabolism is directed at
testosterone biosynthesis due to the absence of SULT2A1 and the ex-
pression of HSD3B2 and HSD17B3. DHEA is then converted to testos-
terone via A4 or androstenediol through the action of HSD3B2 and
HSD17B3, respectively, with HSD17B3 playing a key role in testicular
androgen biosynthesis [47,48]. AKR1C3 expression has been reported
in Leydig cells and may also contribute to testosterone production
[49,50]. Testicular steroid output is predominantly testosterone, with
lower levels of A4 and DHEA also being released into circulation
[51–53]. Androgen and androgen precursor production by the ovary
follows a similar route to that of the testes (Fig. 2).
2.5.3.2. Peripheral tissue activation of androgen precursors. It should be
highlighted that with the exception of testosterone produced by the
testes, the vast majority of C19 steroids produced by the adrenal and
ovaries are inactive androgen precursors. These can, however,
subsequently be converted to active androgens in target cells of
androgen action that express the required enzymatic machinery
(Fig. 3) [45]. More specifically, DHEA can be converted to A4 by
peripheral HSD3B1, with A4 serving as the substrate for the production
of testosterone by AKR1C3 [54]. Subsequent 5α-reduction of
testosterone yields the more potent androgen 5α-dihydrotestosterone
(DHT), with this step therefore serving as a target-specific amplification
of the androgen signal, a pre-receptor activation of testosterone to DHT
[45]. A4 can also be 5α-reduced to 5α-androstanedione prior to
conversion to DHT by AKR1C3, thereby bypassing testosterone
(Fig. 3) [45,55]. Indeed, the enzyme steroid 5α-reductase 1 (SRD5A1)
catalyzes the 5α-reduction of A4 more efficiently than that of
testosterone [56,57]. This so called “alternate 5α-androstanedione”
pathway is favored in tissues with predominant SRD5A1 expression and
in conditions such as castration-resistant prostate cancer in which the
expression of SRD5A1 is upregulated and that of SRD5A2 is
downregulated [55,58]. As SRD5A2 does not demonstrate the same
substrate preference, tissues expressing this isoform are thought to
follow the more conventional pathway of conversion to testosterone,
Fig. 2. Schematic overview of steroidogenesis in the gonads. Steroidogenic pathways in the testicular Leydig cells are shown in the black box, while those in the
ovaries are shown in the grey box and are further subdivided into the theca and granulosa cells. Arrows are labelled with the catalyzing enzyme and isoform where
appropriate. Essential accessory proteins are also indicated: cytochrome b5 (b5); cytochrome P450 oxidoreductase (POR); ferredoxin (FDX); ferredoxin reductase
(FDXR); PAPS synthase (PAPSS); steroidogenic acute regulatory protein (StAR).
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prior to 5α-reduction [56]. Moreover, although the liver undoubtedly
makes the major contribution to steroid metabolism, most peripheral
tissues also possess enzymatic machinery for inactivation of androgens
(both those obtained from circulation and those produced from inactive
precursors) by phase 1 and 2 metabolism (Section 3). This process of
peripheral cell specific activation and inactivation is known as pre- and
post-receptor steroid metabolism or steroid ” intracrinology”
[45,59–61].
2.5.3.3. The alternative DHT biosynthesis pathway. In selected
circumstances, such as CYP21A2 deficiency and during fetal
development (Section 2.6), accumulation of progesterone and 17OHP
Fig. 3. Schematic overview of androgen biosynthesis. Bioactive androgens (testosterone (T), 5α-dihydrotestosterone (DHT), 11-ketotestosterone (11KT) and 11β-
hydroxytestosterone (11OHT) can be generated by three partially independent pathways which operate across multiple tissues: (1) the classic Δ5 pathway, (2) the
alternative DHT biosynthesis pathway, and (3) the 11-oxygenated androgen pathway. Arrows are labelled with the catalyzing enzyme and isoform where
appropriate. Essential accessory proteins are indicated: cytochrome b5 (b5); cytochrome P450 oxidoreductase (POR); ferredoxin (FDX); ferredoxin reductase (FDXR);
hexose-6-phosphate dehydrogenase (H6PDH); PAPS synthase 2 (PAPSS2); steroidogenic acute regulatory protein (StAR).
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in circulation can lead to the activation of an alternative pathway of
DHT biosynthesis (Fig. 3). This is sometimes referred to as the
“backdoor pathway” to DHT [62]. To enter this pathway,
progesterone and 17OHP are 5α-reduced by SRD5A1 to yield 5α-
dihydroprogesterone and 17α-hydroxydihydroprogesterone,
respectively. These are then subsequently converted to
allopregnanolone and 17α-hydroxyallopregnanolone by the 3α-
reductase activity of AKR1C enzymes. Allopregnanolone can then be
converted to 17α-hydroxyallopregnanolone, which serves as an
excellent substrate for the 17,20-lyase activity of CYP17A1 [30],
yielding androsterone. Androsterone, considered an inactive
metabolite of DHT under normal circumstances, can then be
reactivated by the sequential 17β-reduction and 3α-oxidase reactions
[63–65]. Androsterone has been shown to be the principle circulating
androgen precursor for the alternative DHT biosynthesis pathway in the
male fetus during the second trimester. Interestingly, placental
progesterone has been suggested to serve as substrate for
androsterone biosynthesis in the male fetus via the alternative
pathway which occurs across several non-gonadal fetal tissues [66].
2.5.3.4. The 11-oxygenated androgen biosynthesis pathway. Within the
adrenal, A4 can serve as a substrate for CYP11B1, yielding the 11-
oxygenated androgen precursor, 11OHA4 [67], with conversion of
testosterone to 11β-hydroxytestosterone (11OHT), also occurring
(Fig. 3). However, 11OHA4 is by far the predominant product due to
the significantly higher levels of A4 produced in the zona reticularis
[39]. Notably, the addition of exogenous testosterone does not lead to
increased 11-oxygenated androgen output, thereby confirming that
only locally produced substrates (primarily A4) can be 11β-
hydroxylated [68]. Low levels of 11-ketoandrostenedione (11KA4)
and 11-ketotestosterone (11KT) have also been reported in adrenal
vein samples and are suggested to result from some HSD11B2 activity in
the adrenal [39]. However, differences in the concentration of 11KA4
measured in the adrenal vein and inferior vena cava suggest that 11KA4
is predominantly produced from conversion of 11OHA4 in peripheral
tissue expressing HSD11B2 such as the kidney [39,69]. 11KA4 in turn
serves as a substrate for AKR1C3 expressed in peripheral tissues such as
adipose tissue, yielding 11KT, which binds and activates the human
androgen receptor with an affinity and potency similar to that of
testosterone [45,70–72]. Indeed, a recent study has shown that AKR1C3
catalyzes the conversion of 11KA4 to 11KT with an 8-fold higher
efficiency than that of A4 to testosterone, which may account for higher
levels of peripheral activation [73]. Peripheral or intracrine activation
of 11-oxygenated androgens may therefore play a vital role in
regulating their physiological activity. Interestingly, activation/
inactivation of glucocorticoids and 11-oxygenated androgens work in
an antiparallel manner, with the 11β-hydroxy derivative being the
active glucocorticoid [74,75], while the 11-keto androgens are more
potent than their 11β-hydroxy counterparts [76].
2.5.4. Progestogen and estrogen biosynthesis by the ovary
Steroidogenesis within the ovary is compartmentalized in a cell-
specific manner, with the theca cells mainly producing A4 and pro-
gesterone, while the granulosa cells complete the biosynthesis of 17β-
estradiol (Fig. 2). Ovarian steroidogenesis originates in the theca cells
with the production of A4 via the Δ5 pathway. The resulting A4 (and
testosterone) enters the granulosa cells where the expression of
CYP19A1 (aromatase) results in estrogen biosynthesis. Ovarian steroid
output varies considerably during the course of the menstrual cycle –
17β-estradiol is the primary steroid produced during the follicular
phase, while progesterone is the principal steroid during the luteal
phase [77–79].
In addition to de novo steroidogenesis, it is important to note that
the ovary also utilizes circulating DHEA and A4 of adrenal origin for the
biosynthesis of androgens and estrogens [80]. Suppression of adrenal
androgen output by dexamethasone in healthy, young women with a
regular menstrual cycle leads to a 90% decrease in DHEA(S) output, but
also reduces circulating testosterone and DHT concentrations to one
third of their respective baseline concentrations [81]. While A4 can be
metabolized to testosterone by AKR1C3 in the theca cells, the majority
diffuses to the granulosa cells where the high expression levels of
CYP19A1 results in the production of estrone. HSD17B1 subsequently
catalyzes the conversion of estrone to 17β-estradiol, under the regula-
tion of FSH. Testosterone diffusing from the theca cells also serves as
the substrate for CYP19A1, directly contributing to 17β-estradiol pro-
duction. Theca cells also express high levels of the estrogen sulfo-
transferase enzyme SULT1E1, which preferentially sulfates estrone
yielding the relatively abundant estrone sulfate measured in circulation
[82–84]. However, quantitatively estrogens circulate at significantly
lower levels than androgens. Indeed, androgen secretion by the theca
cells surpasses the secretion of estrogens, while progesterone is the
primary progestogen produced [85]. It should also be noted that the
peripheral aromatization of C19 steroids plays an important role in
peripheral estrogen production, particularly following menopause as
outlined in Section 4.4 below.
3. Principles of steroid metabolism and excretion
Steroids are inherently lipophilic molecules. Metabolic conversions
are therefore required to increase their water-solubility and enable ef-
ficient excretion in urine and bile (Table 1). This metabolism is tradi-
tionally divided into two sequential stages, namely phase 1 and phase 2
reactions [86]. Phase 1 reactions alter the biological activity and at the
same time add or reveal functional groups that function as targets for
subsequent phase 2 reactions. Phase 2 reactions are conjugation reac-
tions that ultimately inactivate the compound and increase polarity and
water solubility, thereby facilitating urinary and biliary excretion. Ad-
ditionally, conjugation with a charged group limits transport over
membranes to active transport, thereby allowing for the concentration
of the metabolite on one side [87,88]. The major phase 1 reactions for
steroids are the reduction of the 3-keto-Δ4 motif, the interconversion of
hydroxy- and keto-groups by HSDs/oxoreductases and additional hy-
droxylations by CYPs.
Although the liver undoubtedly makes the major contribution to
steroid metabolism, most peripheral tissues also possess enzymatic
machinery for aspects of both steroid activation and subsequent in-
activation by phase 1 and 2 metabolism. This localized enzyme ex-
pression controls the local steroid milieu by precursor activation and
inactivation according to tissue-specific needs, a mechanism known as
intracellular pre-and post-receptor metabolism or “intracrinology”
[59].
While phase 1 and phase 2 reactions are classically believed to be
sequential, more recent studies have shown the metabolism of con-
jugated steroids by phase 1 enzymes [89]. Additionally, some steroids
can directly undergo phase 2 metabolism without being subjected to a
phase 1 reaction, e.g. testosterone can be directly conjugated at its 17β-
hydroxy group and corticosteroids through 21-sulfation [90]. Despite
these and other shortcomings [91], the traditional classification in
phase 1 and 2 reactions remains helpful to structure the wide range of
reactions and this classification is used below to guide the reader
through the metabolism of endogenous steroids.
3.1. Phase 1 metabolism of steroids
3.1.1. Steroid A-ring reduction
Reduction of the steroid A-ring 3-keto-Δ4 motif is an essential step
for the inactivation of gluco- and mineralocorticoids and controls the
peripheral activation and inactivation of androgens. A-ring reduction
consists of two sequential reductions, namely the reduction of the Δ4-
double bond followed by the reduction of the 3-keto group to a hydroxy
group [92] (Fig. 4(a)). This leads to the production of a 3α/β-hydroxy-
5α/βH motif common to the biologically inactive, excreted metabolites.
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Among these, the 5β/3α-metabolites are referred to as “tetrahydro”,
while 5α/3α-metabolites are referred to as “5α-tetrahydro”. Im-
portantly, 5α/β-reduction is irreversible, with the stereochemistry of
this reduction playing an important role in regulating the biological
activity of androgens (Section 4.3.2) [93].
5α-Reduction is catalyzed by steroid 5α-reductase (SRD5A) en-
zymes of which there are three main isozymes. However, only two of
these, SRD5A1 and SRD5A2, function as genuine steroid 5α-reductases.
SRD5A1 is mainly expressed in the liver and peripheral tissues [94],
while SRD5A2 is expressed mainly in male reproductive and genital
tissues, with its disruption leading to disordered sex development in
46,XY individuals [95]. SRD5A3 appears to have only minor steroid 5α-
reductase activity, but has been shown to play an important role in N-
linked protein glycosylation [96–98]. In addition, two partially homo-
logous SRD5A genes have been identified (SRD5A2L2 and GPSN2), but
have been shown to be involved in the elongation of very long chain
fatty acids [99]. Steroid 5β-reduction is catalyzed by the aldo-keto-re-
ductase (AKR) family member AKR1D1, which is primarily expressed in
the liver. It is the only human enzyme catalyzing the 5β-reduction of 3-
keto-Δ4 steroids and bile acids [100]. AKR1D1 deficiency leads to se-
verely reduced or abolished urinary 5β-reduced steroid excretion and
hepatic failure [101].
Due to differential tissue expression patterns, with SRD5A isoforms
being widely expressed in peripheral tissues including the liver and
AKR1D1 expression being limited to the liver, 5α-reduced metabolites
inform about global metabolism while 5β-reduced metabolites pre-
dominantly reflect hepatic reduction only. Moreover, SRD5As and
AKR1D1 exhibit different catalytic efficiencies towards structurally
different steroids [57,100], with the result that 5α- and 5β-reduced
metabolites are produced with different ratios for different structural
classes of steroids.
The second step of the A-ring reduction is the reduction of the 3-
keto group to a hydroxy group. These reactions are catalyzed by
members of the aldo-keto reductase family, namely AKR1C1, AKR1C2,
AKR1C3 and AKR1C4. Of these, AKR1C4 is thought to be a liver-spe-
cific enzyme which works in concert with AKR1D1, yielding 5β,3α-
Table 1
List of common circulating steroids and their major urine metabolites. Common abbreviations are shown in brackets.
Serum steroid and abbreviation Major urine metabolite and abbreviation (unconjugated form)
General precursors
pregnenolone, 5-pregnen-3β-ol-20-one (PREG; P5) 5-pregnenediol, 5-pregnen-3β,20α-diol (5PD)
progesterone, 4-pregnen-3,20-dione (PROG; P4) pregnanediol, 5β-pregnan-3α,20α-diol (PD)
17α-hydroxypregnenolone, 5-pregnen-3β,17α-diol-20-one (17Preg; 17OHPreg; 17P5) 5-pregnenetriol, 5-pregnen-3β,17α,20α-triol (5 P T)
17α-hydroxyprogesterone, 4-pregnen-17α-ol-3,20-dione (17OHP; 17OHProg; 17P4) pregnanetriol, 5β-pregnan-3α,17α,20α-triol (PT)
17α-hydroxypregnanolone, 5β-pregnan-3α,17α-diol-20-one (17HP)
Mineralocorticoids and their precursors
11-deoxycorticosterone, 4-pregnen-21-ol-3,20-dione (DOC) tetrahydro-11-deoxycorticosterone, 5β-pregnan-3α,21-diol-20-one (THDOC)
corticosterone, 4-pregnene-11β,21-diol-3,20-dione (CORT; B) tetrahydro-11-dehydrocorticosterone, 5β-pregnan-3α,21-diol-11,20-dione (THA)
5α-tetrahydro-11-dehydrocorticosterone, 5α-pregnan-3α,21-diol-11,20-dione (5α-
THA)
5β-tetrahydrocorticosterone, 5β-pregnan-3α,11β,21-triol-20-one (THB)
5α-tetrahydrocorticosterone, 5α-pregnan-3α,11β,21-triol-20-one (5α-THB)
18-hydroxycorticosterone, 4-pregnene-11β,18,21-triol-3,20-dione (18OHCORT;
18OHB; 18B)
18-hydroxytetrahydro-11-dehydrocorticosterone, 5β-pregnan-3α,18,21-triol-11, 20-
dione
(18OHTHA)
aldosterone, 4-pregnene-11β,21-diol-3,20-dione-18-al (ALDO) tetrahydroaldosterone, 5β-pregnan-3α,11β,21-triol-20-one-18-al (THAldo)
Glucocorticoids and their precursors
11-deoxycortisol, 4-pregnen-17α,21-diol-3,20-dione (S) tetrahydro-11-deoxycortisol, 5β-pregnan-3α,17α,21-triol-20-one (THS)
21-deoxycortisol, 4-pregnene-11β,17α-diol-320-dione pregnanetriolone, 5β-pregnan-3α,17α,20α-triol-11-one (PTONE)
cortisol, 4-pregnene-11β,17α,21-triol-320-dione (F) 6β-hydroxycortisol, 4-pregnen-6β,11β,17α,21-tetrol-3,20-dione (6β-OHF)
cortisol, 4-pregnene-11β,17α,21-triol-3,20-dione (F)
tetrahydrocortisol, 5β-pregnan-3α,11β,17α,21-tetrol-20-one (THF)
5α-tetrahydrocortisol, 5α-pregnan-3α,11β,17α,21-tetrol-20-one (5α-THF)
α-cortol, 5β-pregnan-3α,11β,17α,20α,21-pentol
β-cortol, 5β-pregnan-3α,11β,17α,20β,21-pentol
11β-hydroxyeticholanolone, 5β-androstan-3α,11β-ol-17-one (11β-OHEt)
cortisone, 4-pregnene-17α,21-diol-3,11,20-trione (E) cortisone (E)
tetrahydrocortisone (THE)
α-cortolone, 5β-pregnan-3α,17α,20α,21-tetrol-11-one
β-cortolone, 5β-pregnan-3α,17α,20β,21-tetrol-11-one
11-ketoetiocholanolone, 5β-androstan-3α-ol-17,11-dione (11ketoEt)
“Hybrid steroids”
18-hydroxycortisol, 4-pregnene-11β,17α,18,21-tetrol-3,20-dione (18OHF) 18-hydroxycortisol, 4-pregnene-11β,17α,18,21-tetrol-3,20-dione (18OHF)
18-oxo-cortisol, 4-pregnene-11β,17α,21-triol-3,20-dione-18-al (18oxoF) 18-oxo-tetrahydrocortisol, 4-pregnene-11β,17α,21-triol-3,20-dione-18-al (18oxoTHF)
Androgen precursor metabolites
dehydroepiandrosterone sulfate, 5-androsten-3β-sulfate-17-one (DHEAS) dehydroepiandrosterone, 5-androsten-3β-ol-17-one (DHEA)
dehydroepiandrosterone, 5-androsten-3β-ol-17-one (DHEA) dehydroepiandrosterone, 5-androsten-3β-ol-17-one (DHEA)
16α-hydroxydehydroepiandrosterone (16α-DHEA)
androstenedione, 4-androsten-3,17-dione (A4) androsterone, 5α-androstan-3α-ol-17-one (An; AST)
etiocholanolone, 5β-androstan-3α-ol-17-one (Et)
11β-hydroxyandrostenedione, 4-androsten-11β-ol-3,17-dione (11OHA4; 11β-OHA4) 11β-hydroxyandrosterone, 5α-androstan-3α,11β-diol-17-one (11β-OHAn;
11βOHAST))
17-hydroxyallopregnanolone, 5α-pregnane-3α,17α-diol-20-one (5α-17HP) 17-hydroxyallopregnanolone, 5α-pregnan-3α,17α-diol-20-one (5α-17HP)
Androgen metabolites
testosterone, 4-androsten-17β-ol-3-one (T) androsterone, 5α-androstan-3α-ol-17-one (An; AST)
etiocholanolone, 5β-androstan-3α-ol-17-one (Et)
5α-dihydrotestosterone, 5α-androstan-17β-ol-3-one (DHT; 5α-DHT) androsterone, 5α-androstan-3α-ol-17-one (An; AST)
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metabolites. The other isozymes are expressed in different peripheral
tissue in an tissue-specific manner [54].
While 5α-reduced steroids can be converted to both their 3α- or 3β-
hydroxy epimers (with the 3α-reduction generally being more effi-
cient), 5β-reduced steroids are predominantly converted to the 3α-hy-
droxy epimer as the 5β-reduced bent confirmation of the A/B-ring
sterically does not allow binding in the AKR1C active site for 3β-re-
duction [102,103]. AKR1C2 is the major isoform for 3-reduction to the
3α-hydroxyepimer in peripheral tissue, while AKR1C1 is the most im-
portant isoform for the formation of the 3β-hydroxyepimer [102].
Moreover, AKR1C enzymes are multifunctional and also function as
20α- and 17β-HSDs, with different efficiencies, stereoselectivities and
tissue specific expression [104]. For a comprehensive review of these
enzymes see [54].
3.1.2. Hydroxysteroid dehydrogenation and reduction
The interconversion of hydroxy- and keto-groups (Fig. 4(b–d)) at
positions 11, 17 and 20, greatly contribute to the regulation of steroid
activity via their receptors. These reactions are catalyzed by members
of the short-chain dehydrogenase/reductase (SDR) superfamily and the
AKR superfamily using NAD(P)+/H and are typically reversible. While
most of these enzymes are bidirectional in vitro, in vivo directionality is
dictated by co-factor affinity, cellular redox status and pH
[54,105–107].
3.1.2.1. 11β-hydroxysteroid dehydrogenases. Two isoforms of HSD11B
play a key role in regulating glucocorticoid inactivation and
reactivation by catalyzing the interconversion of 11β-hydroxy- and
11-ketosteroids (Fig. 4(b)). Thereby, they modulate systemic and tissue-
specific glucocorticoid action [74,108]. Additionally, they are involved
in the regulation of mineralocorticoid and 11-oxygenated androgen
activity.
HSD11B1 is a bidirectional enzyme, but primarily catalyzes the
reduction of 11-ketosteroids in vivo as colocalized hexose-6-phosphate
dehydrogenase (H6PDH) regenerates NADPH required for its cortisone
reductase activity, mainly activating cortisone to cortisol [109]. Con-
versely, HSD11B2 functions exclusively as an oxidative enzyme, in-
activating cortisol to cortisone [108]. Both isoforms are involved in the
metabolism of glucocorticoids and 11-oxygenated androgens as
described in Sections 4.2.1 and 4.3.2. Moreover, both HSD11B isoforms
also act on 7-oxygenated C19 steroids whereby HSD11B1 functions as an
epimerase interconverting the 7α- and 7β-hydroxy-stereoisomers via a
7-keto-intermediate, while HSD11B2 only oxidizes the 7α-hydroxy-
stereoisomer [110,111].
3.1.2.2. 17β-hydroxysteroid dehydrogenases. Enzymes from the SDR and
AKR superfamilies regulate the activity of androgens and estrogens by
catalyzing the interconversion of bioactive 17β-hydroxy- and inactive
keto- containing forms (Fig. 4(c)). Excreted metabolites are therefore
predominantly in the keto-form [112]. To date, 14 human enzymes
with 17β-HSD/oxoreductase activities have been identified
[105,106,113]. Generally, these enzymes are multi-functional and
often have overlapping substrate specificities and expression patterns,
allowing for redundant enzymes to cover in case of deficiency of
another enzyme [107,114]. However, certain enzymes have been
identified as major catalysts for specific reactions in androgen and
estrogen metabolism as described in Sections 4.3.2 and 4.4.1.
3.1.2.3. 20-reduction. Glucocorticoids and progesterone can be
modified by 20-reduction with α- or β-stereochemistry prior to
excretion (Fig. 4(d)). Of note, the direct 20α-reduction of
progesterone terminates its progestogenic activity and is
predominantly catalyzed by AKR1C1 [104,115]. 20-reduction of
glucocorticoids is primarily observed for downstream
tetrahydrometabolites as described in Section 4.2.2.
3.1.3. Cytochrome P450-catalyzed steroid oxidations
In addition to the steroidogenic CYP enzymes described in Section
2.2, hepatic xenobiotic-metabolizing members of the CYP superfamily
are able to modify steroid hormones and generate a plethora of minor
steroid metabolites [116]. The reaction repertoire of these enzymes for
steroids includes hydroxylation reactions, further oxidations, and CeC
bond cleavages [9,10]. Hepatic CYPs are promiscuous enzymes ac-
cepting a wide range of substrates with low stereo- and regioselectivity
compared to their steroidogenic counterparts. Therefore, several CYPs
can contribute to the same reaction and the high variation of their
expression levels can make it difficult to assess the enzyme(s) making
the dominant contribution to a specific reaction, with at least 17
Table 2
Graphical representation of the circulating serum steroid metabolome. Major circulating steroids are shown divided into six concentration ranges illustrating their
relative contribution to the total circulating steroid pool.
1-10 μmol/L 100-1000 nmol/L 10-100 nmol/L 1-10 nmol/L 100-1000 pmol/L < 100 pmol/L
DHEAS cortisol corticosterone 17OHP 17OHP 17β-estradiol
cortisone (male) (female, follicular phase) (male)
DHEA 17OHP DOC 17β-estradiol
testosterone (female, luteal phase) 18OH-corticosterone (female, postmenopausal)
(male) pregnenolone aldosterone estrone
progesterone 17OH-pregnenolone 18-oxocortisol (male)
(female, luteal phase) 11-deoxycortisol 11OHT estrone
18-hydroxycortisol progesterone (female, postmenopausal)
A4 (male)
11OHA4 progesterone
11KA4 (female, postmenopausal)
testosterone 17β-estradiol
(female) (female, premenopausal)
11KT estrone
progesterone
(female, follicular phase)
(female, premenopausal)
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hepatic CYPs potentially participating in the metabolism of steroids
[116–118].
A high inter- and intra-individual variability of hepatic CYP activity
results from the strong potential for induction by pharmacological and
natural compounds, the high frequency and number of polymorphisms,
and promoter and copy number variants [119,120]. In addition, dif-
ferential expression profiles of functionally different isoforms of the
CYP3A subfamily during prenatal and early postnatal life complicate
the assessment of hepatic steroid metabolism. CYP3A4 is the most
abundant CYP expressed in the adult liver [121,122] and makes the
major contribution to steroid metabolism. CYP3A5 catalyzes a com-
parable range of reactions as CYP3A4 but its role in drug and steroid
metabolism is limited due to its generally low activity and expression in
a relatively small percentage of individuals [123–125]. CYP3A7 is the
major CYP3A isoform in prenatal and early postnatal life and differs
from CYP3A4 in terms of expression and function. CYPs also contribute
to steroid metabolism in several extra-hepatic tissues, including the
brain, breast and prostate [126–129].
3.1.3.1. Steroid hydroxylations. The hydroxylation by hepatic CYPs
inactivates the steroids and increases their polarity and water
solubility. In some cases, the additional hydroxy groups also serve as
sites for conjugation by phase 2 metabolism. CYP3A4-catalyzed 6β-
hydroxylation is the most common hydroxylation for Δ4 steroids, e.g.
cortisol (Fig. 4(e)), while 6α-hydroxylated pregnanolones are
quantitatively important urine steroid metabolites during pregnancy.
Tetrahydro and hexahydro C21 steroids (e.g. THE and the cortolones)
hydroxylated at 1β- and 6α- are quantitatively important during the
Fig. 4. Schematic overview of the major phase 1
reactions contributing to steroid metabolism. (a)
A-ring reduction to (5α)tetrahydro metabolites. The
formation of 3β,5β-tetrahydro metabolites is sterically
unfavorable (not shown). (b) 11β-oxidation/reduc-
tion by HSD11B1 modulates the bioactivity of gluco-
corticoids, mineralocorticoids and 11-oxygenated an-
drogens. (c) 17β-oxidation/reduction regulates the
bioactivity of androgens and estrogens. (d) 20-re-
duction to a hydroxy group with α- or β-stereo-
chemistry. (e–h) Hydroxylations: major positions are
indicated for different structural steroid classes. (i) 21-
oxidation leading to the formation of the so-called
cortolic acids from cortisol. (j)17,20-cleavage: cor-
tisol, cortisone and their metabolites can undergo
metabolism by 17,20-lyase activity. (k) Microbial 21-
dehydroxylation: steroids excreted with bile can un-
dergo metabolism by the gut microbiome prior to re-
absorption.
L. Schiffer, et al. Journal of Steroid Biochemistry and Molecular Biology 194 (2019) 105439
9
perinatal period [130]. The enzymes responsible for these
hydroxylations is uncertain. The differential substrate specificity,
regioselectivity and catalytic activity of CYP3A4 and CYP3A7 and the
dynamic expression pattern of the two isoforms throughout fetal
development and the first year of life lead to substantial changes in
the hepatic steroid metabolome during this period of life. CYP3A7 is
highly expressed in fetal liver and up to 6 months postnatal but
expression levels gradually decrease over this time. CYP3A4 levels are
low in the fetus and newborn compared to the adult. Thus, there is a
switch from CYP3A7 to CYP3A4 during the first months after birth.
Additionally, the total liver CYP3A content is significantly higher
prenatally followed by a reduction after birth reaching plateau at 6
months [131,132].
In terms of Δ5 steroids, e.g. DHEA, 16α-hydroxylation is the most
frequent hydroxylation detected in adults followed by 7α-hydroxyla-
tion (Fig. 4(f)), while 16β-, 21-, 18- and 15β-hydroxylation are also
observed in neonates [133–136].
Interestingly, hepatic CYPs can also perform some reactions that are
classically catalyzed by steroidogenic CYPs (11β-, 17α- and 21-hydro-
xylation) [137–139]. In fact, CYP2C19 and CYP3A4 can 21-hydroxylate
progesterone and pregnenolone, possibly partially compensating mi-
neralocorticoid deficiency in CAH due to 21-hydroxylase deficiency;
however, the two enzymes are not capable of catalyzing the 21-hy-
droxylation of 17OHP to 11-deoxycortisol [140].
Estrogens can be hydroxylated in various different positions by a
number of CYPs [141]. The formation of catecholestrogens by 2- or 4-
hydroxyation are the dominant reactions (Fig. 4(h)). However, during
pregnancy, estriol, which has a 16α-hydroxygroup, is the main meta-
bolite of fetal DHEA. Estriol predominately originates from the ar-
omatization of 16α-hydroxy C19 steroids by the placenta (Section
2.6.2).
3.1.3.2. Additional steroid oxidations. CYPs can further oxidize hydroxy
groups to their respective keto, aldehyde and carboxylic acids. For
example, 6-keto metabolites can be produced from their hydroxy
precursors [141]. 21-carboxylic acid formation from 21-
hydroxysteroids is also possible (Fig. 4(i)) [142–146].
3.1.3.3. Could a empty line be added before these subheadings as the
heading is difficult to distinguish in the pdf CeC bond cleavages. CYPs can
also catalyze oxidative CeC bond cleavages in multi-step reactions
[10]. Examples for such reactions from steroid biosynthesis are the side-
chain cleavage of cholesterol catalyzed by CYP11A1 and the 17,20-
lyase activity of CYP17A1 producing C19 steroids from C21 substrates
(Section 2.5.3) [113]. Hepatic CYPs may employ similar mechanisms to
catalyze the 17–20 cleavage of 17α,21-dihydroxypregnanes (Fig. 4(j)).
3.1.3.4. Could a empty line be added before these subheadings as the
heading is difficult to distinguish in the pdf Contributions of the gut
microbiome. Metabolism by the gut microbiome is relevant for C17-
deoxy corticosteroids, e.g. mineralocorticoids and their precursors,
which have a high biliary excretion [147]. The resulting metabolites
can be reabsorbed into the portal system and undergo further
metabolism in the liver and kidney before being excreted with the
urine. Reactions catalyzed by different strains of gut bacteria include
(1) A-ring reduction, (2) reduction of the Δ5-double bond, (3) reduction
of 17-keto estrogens and 17-keto androstenes, (4) 17,20-cleavage of
17α-hydroxysteroids, and (5) 16α- and 21-dehydroxylation (Fig. 4(k))
[148–156]. Additionally, reductive 20α/β-HSDs are active in gut
bacteria [151]. Unsurprisingly, steroid metabolism by gut bacteria
has been shown to be influenced by the administration of antibiotics
[157].
3.2. Phase 2 metabolism of steroids
The classic phase 2 conjugation reactions – sulfation and
glucuronidation – increase the polarity and water solubility of the
steroids and thereby facilitate their excretion and concentration in the
urine. Mechanistically, these conjugation reactions proceed via two
subsequent, enzymatically catalyzed reactions: (1) the activation of the
moiety to be attached and (2) the transfer of the moiety from the ac-
tivated donor onto a hydroxy group of the steroid. While the conjugated
product is generally considered to be biologically inactive, rare ex-
ceptions have been identified [91]. Importantly, steroid sulfation is
reversible and sulfated steroids can be hydrolyzed to free steroids by
steroid sulfatase (STS), while glucuronidation is irreversible in humans,
with the exception of the activity of some gut bacteria (Section 3.1.3.4).
Notably, bis-conjugation with the same (e.g. bis-sulfation) [158–162]
or two different groups (e.g. sulfate and glucuronic acid) are possible
[163]. Other conjugation reactions include the methylation of catechol
estrogens, conjugation with cysteine or glutathione, and esterification
with fatty acids as outlined below.
3.2.1. Steroid sulfation and desulfation
Sulfation and desulfation play an essential role in mediating the
activity of selected steroids, specifically Δ5 steroids and estrogens, as
has been comprehensively reviewed recently [40]. Sulfation is the re-
sult of two consecutive enzymatic reactions. Firstly, the inert sulfate
anion is activated by conversion to the universal sulfate donor 3′-
phospho-adenosine-5′-phosphosulfate (PAPS), which is catalyzed by
two human PAPS synthase isoforms, PAPSS1 and PAPSS2 [164]. Sec-
ondly, the sulfate moiety is transferred onto hydroxy or amino groups
by sulfotransferases (SULTs) whereby stereochemistry is retained
(Fig. 5(a)). Sulfation is of particular relevance for Δ5 steroids which are
almost exclusively excreted as their sulfates. Five cytoplasmic SULTs
are involved in the sulfation of steroids in humans: SULT1A1, SULT2E1,
SULT2A1 and two isoforms of SULT2B1 (SULT2B1a and SULT2B1b)
[40,165]. These SULTs have overlapping substrate spectra, but the
major enzymes responsible for the sulfation of selected steroids have
been identified and are presented in Section 4 below.
Notably, although the contribution of bis-sulfates to the steroid
metabolomes of urine, blood and bile was first established in the 1960s
[159,160,166–168], interest in these species has only recently re-
emerged with the development of new methodological approaches
[161,169].
Importantly, sulfation is reversible and unconjugated bioactive
steroids can be regenerated from their sulfates by STS, which is ubi-
quitously expressed in all tissues [40]. STS activity is upregulated in
several steroid-dependent cancers [40] and has been evaluated as drug
target [170,171]. The 17α- and 20α-sulfates of steroid bis-sulfates are
not substrates for STS [172].
3.2.2. Steroid glucuronidation
Glucuronidation makes a substantial contribution to the phase 2
metabolism of Δ4 steroids. UDP-glucuronic acid is the activated donor
molecule for glucuronidation. Subsequently, the glucuronic acid is
coupled with a steroid hydroxy group leading to the formation of the
steroid β-D-glucuronide, whereby the stereochemistry of the steroid in
the respective position is preserved (Fig. 5(b)) [173,174]. These reac-
tions are catalyzed by enzymes of the UGT-glucuronosyltransferase
superfamily (UGTs), with the UGT1A and UGT2B subfamily catalyzing
the glucuronidation of steroids [175]. These UGTs are expressed in the
liver, as well as in a range of extrahepatic tissues [176,177]. A-ring
reduced steroid metabolites are predominantly excreted as 3-glucur-
onides. Notably, the formation of linked di-glucuronides and bis-glu-
curonides is also possible [178].
3.2.3. Methylation of catecholestrogens
The O-methylation of catechols plays an important role in the phase
2 metabolism of estrogens (Section 4.4.1) and is catalyzed by the en-
zyme catechol-O-methyltransferase (COMT) [179]: COMT methylates
2- and 4-hydroxyestrogens, thereby producing the so-called
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methoxyestrogens [180]. The donor molecule for the methyltransfer is
S-adenosylmethionine, which is synthesized from methionine and ATP.
COMT primarily methylates the 2 or 4 position of the catechol substrate
[181,182]. The highest levels of COMT are found in the liver, brain,
kidney, adrenal and lungs [183]. While methylation plays an important
role in inactivating catecholestrogens, this phase 2 conjugation reduces
water solubility as opposed to the classic phase 2 reactions described
above [91].
3.2.4. Steroid thioether formation
Cysteine conjugates of androgens, cortisol and progesterone have
recently been detected in human urine and plasma [184–186]. The
authors proposed a metabolic pathway starting with a dehydrogenation
of the steroid in the liver [187], followed by glutathione S-conjugation
of the steroid and subsequent extracellular degradation of the glu-
tathione moiety leading to a cysteine conjugate which is excreted.
3.2.5. Fatty acid esterification of steroids
Although the physiological relevance has yet to be determined, fatty
acid esterification of pregnenolone, DHEA and androstenediol has been
described [188,189]. Plasma lecithin:cholesterol acyltransferase lo-
cated on high-density lipoproteins can acylate steroids using acyl-CoA
as donor [190]. The steroid fatty acid ester can then be transferred to
other lipoproteins and be taken up by peripheral cells via lipoprotein
receptors [191,192]. Additionally, steroids can be esterified with fatty
acids in peripheral tissues [193].
3.3. Steroid excretion
Steroids are excreted predominantly as their conjugates in the urine
and bile, with urine excretion accounting for approximately 80% of
excretion following exogenous administration [194]. The clearance of
steroid glucuronides generally proceeds faster than the clearance of
steroid sulfates [195], presumably due to the irreversible nature of
glucuronidation in humans.
3.3.1. Urinary steroid excretion
In the kidney, steroid conjugates are transported from the blood
filtrate over the epithelium into the lumen of the nephron. Cellular
uptake is mediated by organic anion symport or exchange. The efflux
from the cell into the lumen is carrier-mediated and makes use of an
electrochemical gradient [196]. The active nature of transport across
the epithelial cells allows for the concentration of steroid conjugates in
the lumen. Urinary excretion of unconjugated steroids is low, ac-
counting for only 5–10% of the total urine steroid pool. The urine
metabolomes of all classes of steroids will be discussed in detail in
Section 4. Interestingly, enzymes with 20β-HSD and 17,20-lyase ac-
tivity have been recently identified in a microbial inhabitant of the
urinary tract [197].
3.3.2. Biliary excretion of steroids
Steroids passing the canalicular membrane of the hepatocyte are
excreted in the bile. The rate of biliary excretion determines the
quantitative contribution of the gut microbiome to the metabolism of
the respective steroid. Excretion with the feces is low as steroids are
reabsorbed in the gut [198]. 17-deoxysteroids (mineralocorticoids and
precursors) have high biliary excretion as opposed to 17-hydroxy C21
steroids like cortisol [147]. Steroid conjugates represent the major
fraction of biliary excreted steroids [147,199–202] and the dominance
of bis-sulfates [168] led to the hypothesis that bis-sulfates originating
from the liver are preferably excreted with the bile, while glucuronides
preferably undergo renal excretion [200]. Biliary excretion is increased
during pregnancy [201,203,204] and an equal quantitative contribu-
tion of urinary and fecal excretion has been suggested during the
newborn period [204]. The steroid metabolome in the feces comprises
unconjugated, mono- and bis-sulfated steroids [203] and up to 90% of
Fig. 5. Schematic overview of the major phase 2 reactions contributing to steroid metabolism – sulfation (a) and glucuronidation (b). Important target
positions of steroid conjugation are indicated, with stereochemistry for the different structural classes of steroids.
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steroids in feces during pregnancy are unconjugated [205]. Notably,
estrogens seem to undergo higher biliary excretion than other steroids,
but also higher reabsorption leading to low fecal excretion [194,206].
Gut microbiota have hydrolase activity for steroid conjugates and glu-
curonides in particular [148], leading to the high proportion of un-
conjugated steroids compared to bile, and conjugate hydrolysis might
be a prerequisite for reabsorption [207].
3.3.3. Salivary steroids
Steroids are also excreted in saliva. Indeed, the measurement of
salivary steroids is becoming an emerging tool for the diagnosis and
treatment monitoring of steroidogenic disorders due to the ease of
saliva collection [208]. Unconjugated steroids passively diffuse over the
membranes of the acinar cells in the salivary glands independent of
salivary flow rate [209]. Their levels in saliva therefore provide a
measure of their free concentrations in serum [210]. However, steroids
can be subject to metabolism while crossing the acinar cells, which
affects their levels in saliva. For example, the presence of HSD11B2 in
the parotid gland makes salivary cortisone a useful marker for serum
free cortisol and adrenal stimulation [211–213]. Conjugated steroids
enter saliva by ultrafiltration through the extracellular space between
the acinar cells and their salivary levels are highly flow rate dependent
as has been shown for DHEAS [209].
4. Serum and urine steroid metabolomes
4.1. The mineralocorticoid metabolome
The primary mineralocorticoid in circulation is aldosterone. It is
estimated that approximately one third of aldosterone circulates in the
free form, with the remainder bound to corticosteroid binding globulin
(CBG) and serum albumin [214]. Serum mineralocorticoid assays pri-
marily focus on the measurement of aldosterone only, although the
precursors DOC, corticosterone and 18-hydroxycorticosterone are also
detectable in serum (Table 2) [215].
Aldosterone, as well as its immediate precursors, contain a Δ4 moiety.
Metabolism of these steroids is therefore primarily by sequential 5α/β-
and 3α-reductions in the liver (Fig. 6). DOC and aldosterone are both
preferentially 5β-reduced by AKR1D1 followed by 3α-reduction yielding
the tetrahydro metabolites, tetrahydrodeoxycorticosterone (THDOC) and
tetrahydroaldosterone (THAldo), respectively. Similarly, 18-hydro-
xycorticosterone is converted to the tetrahydro metabolite, 18-hydroxy-
tetrahydro-11-dehydrocorticosterone (18OHTHA), but this requires the
additional conversion of the 11β-hydroxy group to an 11-keto group, a
reaction catalyzed by HSD11B2 [216–218]. Corticosterone can be con-
verted to 11-dehydrocorticosterone by the action of HSD11B2 in the
kidney, which prevents the activation of the mineralocorticoid receptor
(MR) by corticosterone though corticosterone’s MR-activating potency is
considerably lower than that of aldosterone [219]. Unlike the other
mineralocorticoid precursors, both corticosterone and 11-dehy-
drocorticosterone can either be 5α- or 5β-reduced, prior to 3α-reduction
leading to a tetrahydro and a 5α-tetrahydro metabolite for each. These
are tetrahydro-11-dehydrocorticosterone (THA) and 5α-tetrahydro-11-
dehydrocorticosterone (5α-THA) for 11-dehydrocorticosterone, and tet-
rahydrocorticosterone (THB) and 5α-tetrahydrocorticosterone (5α-THB)
for corticosterone, the latter being dominant (Fig. 6). Importantly, during
neonatal life, THA, 5α-THA and the polar metabolite 6α-hydroxy-THA
are the more relevant corticosterone metabolites (Fig. 4(g)) [130]. As
with most steroid metabolites, the majority of these are subsequently
glucuronidated in the liver and excreted in urine [220–222]. Aldosterone
is preferentially 18-glucuronidated in the liver by UGT2B7 and UGT1A10
[223]. UGT2B7 also efficiently conjugates 5α-dihydroaldosterone and
THAldo, while UGT2B4 glucuronidates only THAldo [224]. It should,
however, be noted that aldosterone is also glucuronidated directly to
aldosterone-18β-glucuronide within the kidney, which has been pro-
posed to be catalyzed by UGT2B7 [225]. Indeed, it has been estimated
that aldosterone-18β-glucuronide and THAldo-glucuronides contribute
5–15% and 15–40% towards the daily urinary excretion of aldosterone
[221,226]. It has also been found that THAldo-glucuronides are con-
sistently five-fold more prevalent than aldosterone-18β-glucuronide ir-
respective of sodium intake [221]. Finally, it should be noted that en-
zymes expressed by anaerobic bacteria in the human gut have been
shown to be able to convert aldosterone to THAldo, 3β,5α-THAldo,
3α,5α-THAldo as well as 20β-dihydroaldosterone in a species-specific
manner [150]. Biliary excretion and metabolism by the gut microbiome
is also relevant for the 17-deoxy mineralocorticoid precursors and their
metabolites as described in Section 3.1.3.4 [227].
4.2. The glucocorticoid metabolome
4.2.1. Cortisol and cortisone interconversion
The primary active glucocorticoid in circulation is cortisol, which is
produced by the adrenal cortex (Section 2.5.2). Inactivation of cortisol
to cortisone, which cannot activate the glucocorticoid receptor or the
MR, subsequently occurs in peripheral mineralocorticoid target tissue,
such as the kidney, the colon and the salivary glands all of which ex-
press HSD11B2 [74]. HSD11B2 converts cortisol to cortisone to protect
the MR from activation by cortisol, thus allowing the dedicated MR
agonist aldosterone to bind [228–231]. The placenta is another im-
portant tissue expressing HSD11B2 as to inactivate maternal cortisol,
thereby limiting fetal exposure [74].
Cortisone is in-turn reactivated to cortisol by the action of HSD11B1
expressed predominantly in the liver, as well as some peripheral tissues
such as adipose tissue, muscle, skin and bone [74,232–235]. Although
the ratio of cortisol to cortisone remains relatively constant in circu-
lation, studies with radiolabeled tracers have shown that there is con-
stant interconversion of cortisol and cortisone [236]. Tissue-specific
expression of HSD11B1 allows for local intracellular cortisol reactiva-
tion independently of circulating cortisol levels [74]. Interestingly,
HSD11B1 expression is low/undetectable at birth, but thereafter in-
creases rapidly, with adult levels reached after 6–12 months [237]. As a
result, cortisone and the resulting 11-keto-metabolites (e.g. tetra-
hydrocortisone) are substantially increased during the neonatal period
[74].
While HSD11B1 can function bi-directionally in vitro, it acts pre-
dominantly as a reductase in vivo due to localized co-expression on the
ER membrane with H6PDH, which produces NADPH that drives the
reductase activity of HSD11B1. A deficiency of H6PDH therefore leads
to an impairment of HSD11B1 reductive function and apparent corti-
sone reductase deficiency [238].
A vital aspect to consider when measuring cortisol and cortisone is
their diurnal secretion rhythm [239]. This follows a distinct pattern
with nadir concentrations around midnight and the highest levels ob-
served between 3 and 5 a.m., although the exact timings can show
inter-individual variability [240–242]. Any healthy individual’s serum
cortisol concentration will be significantly higher in the morning than
at midnight. This rhythm can be lost in times of severe illness or stress,
with significant increases in circulating cortisol throughout the entire
24-h period observed in patients with sepsis and during surgical pro-
cedures [243,244]. To account for the diurnal rhythm of glucocorti-
coids, when assessing serum glucocorticoid concentrations, comparator
samples should be drawn at the same time of day. With urine collec-
tions, the time of collection is similarly important – a one-off spot urine
collected in the morning will differ greatly from a spot urine collected
in the afternoon, a problem that can be overcome by 24-h urine col-
lections, which provide output data for the entire 24-h period in-
dependent of diurnal variation.
The majority of cortisol circulates bound to proteins, with 80–90%
bound to CBG. CBG also binds other steroids such as cortisone, 17OHP,
progesterone, DOC, corticosterone, and, to a lesser degree, aldosterone,
testosterone and 17β-estradiol. The remaining cortisol is either bound
to albumin (5–10%) or circulates in its free (active) form (<10%)
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[245–247].
The serum levels of the glucocorticoid precursors, progesterone,
17OHP and 11-deoxycortisol are all ≤10nM in the healthy population
and therefore significantly lower than that of cortisol (ranging from 100
to 600 nM) and cortisone (ranging from 30 to 100 nM) (Table 2). The
concentrations of cortisol, cortisone and 11-deoxycortisol are similar in
men and women, though women who have increased estrogenlevels
due to oral or transdermal contraceptives or pregnancy, have increased
total serum cortisol due to an increase in CBG (and in pregnancy, also
an increase in total cortisol production from the 22nd week of gestation
onwards) [248–250].
4.2.2. Downstream glucocorticoid metabolism
As with all steroids containing the Δ4 steroid moiety, the dominant
first steps in the metabolism of glucocorticoids is the 5α/5β-reduction
in the liver (Section 3.1.1). Interestingly, while 17OHP and cortisol can
be either 5α- or 5β-reduced, 11-deoxycortisol and cortisone are pre-
dominantly 5β-reduced [108]. All products are subsequently 3α-re-
duced yielding the respective tetrahydro or 5α-tetrahydro metabolites
(Fig. 7), which are detectable in urine. A number of the tetrahydro
metabolites can also be further metabolized by 20α- or 20β-HSDs
[251,252]. Of quantitative importance is the 20α/β-reduction of tet-
rahydrocortisol (THF), yielding the so called cortols (α- and β-cortol),
and that of tetrahydrocortisone (THE), which yields the equivalent
cortolones (α- and β-cortolone) [253]. While all four members of the
human AKR1C enzyme subfamily can catalyze the reduction to the 20α-
hydroxy group, AKR1C1 is the predominant 20-ketosteroid reductase in
human [104]. Although a 20β-HSD reducing cortisone in zebrafish has
been characterized as a member of the SDR family [254] and carbonyl
reductase 1 has been described a relevant 20β-HSD for cortisol in hu-
mans [255], the human enzyme(s) responsible for the formation of the
20β-hydroxy isomers of the cortols and cortolones has not yet been
identified. Cortisone and cortisol reduced at 20α- and 20β- while re-
taining the Δ4 moiety are also excreted in significant amounts, i.e.
20α(andβ)-dihydrocortisone and 20α-(andβ)-dihydrocortisol [256].
THF and THE can also be subject to an elusive side-chain cleavage
reaction not catalyzed by CYP17A1, producing C19 metabolites of glu-
cocorticoid origin. Thereby, glucocorticoids contribute predominantly
to urinary excretion of 11β-hydroxyetiocholanolone and 11-ketoe-
tiocholanolone. While 5α-THF is also a substrate for this side-chain
cleavage reaction, this reaction is catalyzed less efficiently [257]. As a
result, the glucocorticoid contribution to urine 11β-OHAn is very low in
healthy individuals, with the majority originating from the metabolism
of the androgen 11OHA4 (Section 4.3.2) [258].
Cortisol can also be 6β-hydroxylated by CYP3A4 expressed in the
liver, resulting in 6β-hydroxycortisol (6β-OHF) [259,260]. Orally ad-
ministered hydrocortisone results in relatively increased circulating 6β-
OHF, in comparison to the other glucocorticoid metabolites, due to the
hepatic first pass effect after the oral ingestion. 18-Hydroxycortisol is
also a product formed in zona fasciculata of the adrenal, with the minor
Fig. 6. Schematic overview of the pathways linking mineralocorticoids and their precursors to their urine metabolites. The pathway of mineralocorticoid
biosynthesis is indicated on the left. The metabolism of each steroid is shown from left to right and the structures of the major urine products are shown. Phase 2
conjugation reactions are not indicated in the figure.
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downstream product 18-oxocortisol also being produced. These meta-
bolites are often referred to as “hybrid steroids” as they require enzy-
matic machinery from both the glucocorticoid and mineralocorticoid
pathways [261–263]. They are particularly important in patients in
glucocorticoid remediable aldosteronism or with aldosterone-producing
adenomas associated with KCNJ5 mutations [261,264–272]. Hydro-
xylation of the tetra- and hexahydro-metabolites of cortisol (e.g., THE
and the cortolones) at 1β- and 6α-carbon position is quantitatively
important in the neonatal period. [130]. The glucocorticoid precursor
17OHP can be converted to 17α-hydroxypregnanolone (17HP) via 5β-
reductase and 3αHSD activities. The subsequent 20α-reduction of 17HP
yields the metabolite pregnanetriol (PT, 5β-pregnane-3α,17α,20α-
triol).
The majority (> 90%) of the glucocorticoid metabolites described
above are glucuronidated in the liver prior to urinary excretion as
mono-glucuronides with glycosidic bonds added at positions 3 or 21.
UGT2B7 has been shown to efficiently catalyze the conjugation of
glucocorticoids [224]. Metabolites retaining the Δ4 moiety are excreted
to a greater degree unconjugated. Two studies report unconjugated
excretion of the following individual steroids: cortisol (30%), cortisone,
20αDHE, 20βDHE, 20βDHF (40–60%); 20αDHF, 6β-OH-cortisol, 6β-
OH-E and 18-OH-cortisol (80–100%) [273,274]. Urine free cortisol, i.e.
the free fraction of total, non-metabolized urine cortisol, is commonly
measured in clinical chemistry laboratories for the diagnosis of Cush-
ing’s syndrome [275] whereas gas chromatography-mass spectrometry
(GC-MS) measures total urine cortisol following deconjugation.
4.3. The androgen metabolome
4.3.1. Androgens in circulation
Androgens and their precursors are derived from both the adrenal
cortex and the gonads as described in Section 2.5.3 above. It is im-
portant to note the that circulating androgen metabolome consist of
both active androgens and androgen precursors, with both of these
contributing to androgen action in target tissues [45]. Downstream
metabolites can also be measured in circulation [60]. The best-known
circulating androgen in both men and women of reproductive age is
testosterone (Table 2). Circulating testosterone concentrations in men
are approximately 10-fold higher than those of women, due to the
dedicated biosynthesis in the testes, together with a very minor
Fig. 7. Schematic overview of the pathways linking glucocorticoids and their precursors to their urine metabolites. The glucocorticoid biosynthetic pathway
is shown on the left. The metabolism of each steroid is shown from left to right and the structures of the major urine products are shown. Phase 2 conjugation
reactions are not indicated in the figure.
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contribution from the adrenals (Section 2.5.3.1). Conversely, female
androgens are equally derived from the adrenal glands and the ovaries
(Section 2.5.3.1), which are each estimated to contribute 25% towards
the circulating levels of testosterone in both pre- and postmenopausal
women. The remaining 50% originates from the peripheral conversion
of androgen precursors such as A4 to testosterone [276–278]. Androgen
precursors in circulation include DHEA, its sulfate ester DHEAS, A4,
11OHA4, androstenediol and androstenediol sulfate. In fact, the cir-
culating levels of DHEAS dwarf those of any other steroid in circulation
(Table 2) and DHEAS is the only human steroid that circulates in mi-
cromolar concentrations. However, it is primarily thought to serve as an
inactive waste product of adrenal steroidogenesis, produced to prevent
an excessive androgen load [39,40,279]. The production of adrenal
androgen precursors increases at adrenarche at 6–9 years of age, peak
between 20 to 30 years of age, and subsequently decline gradually with
age (Section 2.5.3.1). Gonadal androgen production is initiated for a
short period of time during minipuberty in infancy, but then remains
dormant until puberty. Following full initiation at puberty gonadal
androgen production decreases significantly after menopause in
women, while in men the testicular output of testosterone gradually
decreases with age, resulting in significantly lower combined androgen
levels in men aged 60 and over [24,280–282]. In women, testosterone
and A4 demonstrate cyclic changes in concentration during the course
of the menstrual cycle due to the ovarian contribution, with levels
peaking mid-cycle [283,284].
Within circulation, most active sex steroids are bound to the plasma
proteins sex hormone binding globulin (SHBG) or albumin and only a
small fraction (1–2%) circulates unbound, which is the only form in
which testosterone is accessible to the target tissues. Sex steroid-
binding plasma proteins, therefore, play a key role in the regulation of
androgen action. SHBG binds sex steroids (including active androgens
and estrogens) with high affinity (nanomolar ranges) and specificity
[285–287]. Although albumin binds all unconjugated steroids with low
affinities (micromolar ranges), it makes a significant contribution to
steroid binding due to its high abundance [45,287]. While SHBG binds
the active androgens DHT and testosterone with high affinity, the af-
finity of SHBG for androgen precursors such as DHEA is substantially
lower. Moreover, the conjugated precursor, DHEAS, circulates only in
its free form.
While the levels of 11-oxygenated androgens and their precursors
have been shown to be significantly elevated in patients with polycystic
ovary syndrome (PCOS) and 21-hydroxylase deficiency [41,69], one
study reported that the circulating levels of 11KT were also higher than
that of testosterone in a healthy female control group (BMI
21.2–26.1 kg/m2) [41]. This and other recent findings have led some to
suggest that 11KT may in fact be the most physiologically relevant
androgen in women, though more work is needed to investigate this
[288]. However, although multiple studies have measured the circu-
lating concentrations of 11-oxygenated androgens in healthy control
groups, there are significant variations in the levels reported and as
such, no reference ranges have been established to date
[39,41,68,69,289]. Nonetheless, it is clear that 11OHA4, the major 11-
oxygenated androgen precursor produced by the adrenal, circulates at
higher levels than A4. 11KA4 is the next most abundant 11-oxygenated
androgen precursor in circulation (Table 2) [39,41,68,69,289]. Sig-
nificantly, a recent study has revealed that unlike the classical andro-
gens, the circulating levels of 11-oxygenated androgens do not decrease
with age in women, suggested to be due to the involution of the zona
reticularis with age and the appearance of areas co-expressing HSD3B2
and CYB5A [289].
4.3.2. Downstream androgen metabolism
The contributions of androgen precursors of adrenal and gonadal
origin are often overlooked when considering the total androgen pool.
The primary reason for this is that, while androgen precursors are ac-
tivated in peripheral target tissues, this is often, but not always, fol-
lowed by subsequent inactivation within the same tissue, thus with the
result that much of the active androgen is never accounted for in cir-
culation (Section 2.5.3.2). It is therefore important to consider both
androgen precursors and metabolites when accessing androgen action.
While androgen precursors and active androgens can be measured in
serum, it is often more convenient to measure their metabolites in urine
(Table 3).
Undoubtedly, the most important step in androgen activation and
inactivation is the 5α-/5β-reduction of the Δ4 steroid moiety common
to all androgen precursors as well as the potent androgen testosterone
(Fig. 8). This moiety is selectively 5α-reduced by the action of steroid
5α-reductase enzymes within target tissues. Those androgens and
Table 3
Graphical representation of the targeted urine steroid metabolome. Major urine steroids are shown divided into six concentration ranges illustrating their relative
contribution to total 24 h urine steroid metabolite excretion. Divisions are based on respective median values as urine metabolites demonstrate substantial variation
between individuals and the 25-75th percentiles may overlap groups.
1000-3000 μg/24 h 700-1000 μg/24 h 400-700 μg/24 h 150-400 μg/24 h 20-150 μg/24 h <20 μg/24 h
5α-THF (male) 5α-THF (female) β-cortol (male) 17HP (male) 17HP (female) PTONE
THF α-cortolone (female) PT (male) PD 5 P T (female) THDOC
α-cortolone
(male)
Et (female) 11β-OHAn (male) 5 P T (male) THS 5α-17HP
An (female) PT (female) THAldo
THE 5α-THB 18OHTHA
An (male) α-cortol THA
Et (male) 11β-OHEt 5α-THA
β-cortol (female) THB
11ketoEt cortisol
β-cortolone cortisone
DHEA 6β-OHF
16α-DHEA
11β-OHAn (female)
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precursors that escape the tissue specific activation via 5α-reduction are
metabolized within the liver, which expresses both 5α- and 5β-re-
ductases [54,94,100]. Unlike 5α-reduction, which is required to pro-
duce the potent androgen DHT, AKR1D1-catalyzed 5β-reduction acts
only as an inactivation step. Even 5β-DHT, the product of the 5β-re-
duction of testosterone, is an inactive androgen metabolite [54]. Fol-
lowing 5α/5β-reduction, androgen metabolites are subject to reduction
of the 3-keto group with predominant 3α-stereoselectivity [54]. Im-
portantly, 3α,5α-reduced metabolites can potentially be converted back
to the 3-keto metabolite by oxidative 3α-HSDs such as in the alternative
DHT biosynthesis pathway (Section 2.5.3.3).
The majority of 5α/β-3α-metabolites of testosterone and DHT,
which contain a 17β-hydroxy, are converted to 17-keto steroids by the
action of the oxidative 17β-HSDs, HSD17B2 and HSD17B4 [106]. As a
result, androgen metabolites are excreted with a 17-keto/17β-hydroxy
ratio of approximately 10:1 [112].
Therefore, the primary urine androgen metabolites are androsterone
(An; 5α-androstan-3α-ol-17-one) and etiocholanolone (Et; 5β-andro-
stan-3α-ol-17-one) (Table 3). While, A4 and testosterone can be meta-
bolized to either androsterone or etiocholanolone, DHT is 5α-reduced
and thus only reflected in the androsterone fraction.
Both An and Et are subject to glucuronidation at the 3 position. This
phase 2 metabolism can occur in the liver or within peripheral target
tissues. The glucuronidation of C19 steroids is catalyzed by three
members of the UGT2B subfamily, namely: UGT2B7, UGT2B15 and
UGT2B17 [175]. The three enzymes have differential regioselectivity
and substrate specificity for the 5α/β-stereoisomers [290]. UGT2B7
glucuronidates only the hydroxy group at position 3, but not in position
17 and preferentially conjugates 5α- over 5β-androstanes. UGT2B7 is
the most efficient UGT for androstanediol conjugation [176]. UGT2B15
does not target the 3-hydroxy group, but conjugates the 17-hydroxy
group in the androstane-3α,17β-diols, such as testosterone or DHT, and
prefers the 5α-stereoisomers. Similarly, UGT2B17 has a preference for
the 17β-hydroxy group in the androstane-3α,17β-diols, but conjugates
the 3α-hydroxy group of An and Et with Et being the preferred substrate
[290]. UGT2B17 has highest activity of all UGTs towards An, testos-
terone and DHT. UGT2A1 may also contribute to the glucuronidation of
testosterone [291]. Interestingly, UGT2B15 which is expressed in adi-
pose tissue has been shown to demonstrate a higher activity in obese
individuals, which may contribute to the increased levels of 3α-
Fig. 8. Schematic overview of the pathways linking androgens and their precursors to their urine metabolites. Major serum androgen precursors and
androgens are shown on the left. The metabolism of each steroid is shown from left to right and the structures of the major urine products are shown. 5α-
dihydrotestosterone (DHT), the most potent androgen, is derived from testosterone by 5α-reduction and, thus, its formation is only reflected by urine androsterone.
Phase 2 conjugation reactions are not indicated in the figure.
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androstanediol glucuronide observed in obesity [292,293]. While Δ5
steroids like DHEA and pregnenolone are excreted almost exclusively as
sulfates, sulfation of other C19 steroid metabolites are considered minor
phase 2 reactions. SULT2A2 can target 3α- and 17β-hydroxyl groups
and has been shown to sulfate An, testosterone and DHT [294,295].
Hydroxy groups in positions 16β, 17α/β and 18 are also important
targets for sulfation of C19 steroids [159,296–298].
Major urine androgen precursor metabolites include DHEA and
16α-hydroxy-DHEA. Circulating DHEA is readily 16α-hydroxylated by
CYP3A4/7 within the liver [136,299]. The abundant conjugated an-
drogen precursor, DHEAS, is water-soluble and is largely excreted in an
unmodified form as represented by the urinary DHEA fraction following
deconjugation.
Urinary metabolite excretion deriving from the 11-oxygenated an-
drogen precursor 11OHA4 is well understood. 11OHA4 undergoes se-
quential 5α- and 3α- reduction yielding 11β-OHAn, which is readily
quantifiable in urine (Table 3). It should be noted that although 11β-
OHAn can also derive from cortisol metabolism (Section 4.2.2), this
only contributes to approximately 5–10% of the measured levels, with
at least 90% originating from 11OHA4 [258]. The metabolism of the
active 11-oxygenated androgen, 11KT, has yet to be fully elucidated.
Similarly, only a few studies have investigated the potential conjuga-
tion of 11-oxygenated steroids. While these steroids do appear to be
glucuronidated, the limited data at hand suggests that glucuronidation
of these steroids is less efficient than what is observed for the classic
androgens [300].
4.4. The estrogen and progestogen metabolomes
4.4.1. The estrogen metabolome
The primary estrogens in circulation are estrone, estrone sulfate and
17β-estradiol, with 17β-estradiol considered the biologically active
form [82,301–303]. In premenopausal women, these estrogens are
predominantly produced by the ovaries (Section 2.5.4), but estrogens
are also synthesized in peripheral tissues expressing aromatase, such as
adipose tissue, using adrenal-derived androgen precursors. This per-
ipheral production of estrogens is especially important in post-
menopausal women and men [61]. It should be noted that this per-
ipheral estrogen production often functions in a paracrine and
intracrine manner and as such circulating concentrations are not re-
flective of the concentrations achieved locally [304,305]. Circulating
levels of estrogens vary greatly during the course of the menstrual cycle
and decrease significantly in postmenopausal women (Table 3)
[306–308]. Notably, estrone sulfate is the predominant estrogen in
circulation for both men and premenopausal women and serves as a
biologically inactive reservoir for the generation of active estrogens in
target tissues [40,309,310]. Like with androgens, the majority of un-
conjugated estrogen circulates bound to SHBG with high affinity and
albumin with low affinity [285–287]. Another similarity to androgens
is the regulation of estrogen potency by HSD17B enzymes, with
HSD17B1 and HSD17B2 being the two most prominent isoforms in-
volved in estrogen metabolism. HSD17B1 reduces estrone to the most
active estrogen, 17β-estradiol. HSD17B2 catalyzes the reverse oxidative
reaction of 17β-estradiol to estrone in addition to its high activity to-
wards androgens. Further metabolism of both estrone and 17β-estradiol
can yield estriol. Estrone undergoes 16α-hydroxylation and HSD17B1
catalyzed reduction, while 17β-estradiol only requires 16α-hydroxyla-
tion [311–314]. CYP3A4 is the major enzyme responsible for the 16α-
hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and
CYP3A5 can also catalyze the reaction [315,316]. Conversely, CYP1A2
is the dominant enzyme catalyzing the 16α-hydroxylation of 17β-es-
tradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this
activity [317]. Estriol is rapidly excreted in urine and, as a result, serum
levels are low to undetectable [318].
Both estrone and 17β-estradiol can also undergo hydroxylation at
position 2 and 4 [141,317,319–321]. These reactions are catalyzed by a
variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1
and CYP3A4 in peripheral tissues. In the liver approximately 80% of
17β-estradiol is hydroxylated to the 2 position and 20% at the 4 posi-
tion [322]. 2- and 4-hydroxy groups on the A-ring can be methylated as
introduced in Section 3.2.3. Other reported hydroxylations include
those at 6α, 6β, 7α, 12β, 15α, 15β, 16α and 16β positions as well as
further oxidation to a 6-ketone or 9-11-dehydrogenation
[141,322–324].
Estrogens and catecholestrogens are efficiently sulfated at several
positions [325–327]. SULT1E1 is the major SULT for estrogen sulfation
[328,329], while SULT1A1 and SULT1A3 also sulfate estrogens, but
with a lower affinity [327].
Glucuronidation of estrogens is catalyzed by members of the UGT1A
and UGT2B7 subfamilies with the UGT1A isoforms making the largest
contribution to the glucuronidation of estrone and 17β-estradiol. Estriol
and 16α-hydroxyestrone are conjugated at the 3-hydroxygroup by
UGT1A10 and at the 16α-hydroxy group by UGT2B7 [330,331].
Catcholestrogens can additionally be glucuronidated in positions 2 and
4 [332].
4.4.2. The progestogen metabolome
Progestogens are compounds with progestational activity, referring
to their induction of a secretory endometrium to support gestation
[333]. The only true natural progestogen is progesterone. Levels change
substantially during the course of the menstrual cycle, peaking during
the luteal phase (Table 3). Low levels of circulating progesterone are
also detectable in men [334]. Progesterone primarily circulates bound
to CBG. During the second and third trimesters of pregnancy placental
trophoblasts produce large amounts of progesterone, which displaces
glucocorticoids from CBG [287,335].
Progestogens are primarily metabolized by the liver largely to form
pregnanediols and pregnanolones [336,337]. Progesterone is metabo-
lized to pregnanediol (PD, 5β-pregnane-3α,20α-diol) in three steps.
AKR1D1 catalyzes the 5β-reduction followed by members of the AKR1C
enzyme family catalyzing subsequent 3α- and 20α-reductions. Alter-
natively, progesterone can first be reduced to 20α-hydro-
xyprogesterone, which can then be further 5β-reduced by AKR1D1 and
3α-reduced by AKR1C1–4 [103]. PD is efficiently glucuronidated at
position 3, resulting in pregnanediol-3-glucuronide being the major
progesterone metabolite identified in urine. Progesterone metabolites
reduced at 5α position are subject to extrahepatic 6α-hydroxylation,
which is distinct from the hepatic 6α-hydroxylation active on Δ4 ster-
oids [338].
5. Steroid metabolome profiling by mass spectrometry
5.1. Current state-of-the-art techniques in steroid analysis
Mass spectrometry is a powerful technique with which multiple
steroids can be measured within a single analytical run. Despite the
wealth of information that can be achieved by these methods, uptake in
the clinical setting is still limited, primarily due to the cost of the
technology and the limited availability of the required expertise.
Currently, gas chromatography-mass spectrometry (GC-MS) is the
preferred method for the analysis of urine steroids in research labora-
tories due to the unparalleled resolution offered by this technique
[339,340]. However, of late, there are increasing efforts to develop both
ultra-high performance liquid chromatography-tandem mass spectro-
metry (UHPLC-MS/MS) and ultra-high performance supercritical fluid
chromatography-tandem mass spectrometry (UPHSFC-MS/MS) methods
for the screening of multiple urine steroids [341,342]. An advantage of
these techniques is that deconjugation is not mandatory, unlike with
GCeMS. The idea of quantifying conjugated urine steroid metabolites is
therefore gaining momentum in the field. This may be advantageous as
some steroids with secondary sulfate groups (bis-sulfates), or glucur-
onides can be resistant to common hydrolysis procedures.
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The introduction of high throughput UHPLC-MS/MS has led to a
substantial increase in the use of mass spectrometry-based assays for
steroid profiling, especially in serum, as UHPLC-MS/MS is a more ac-
curate and reliable technique without the cross-reactivity issues that
plague immuno-based assays. Indeed, there is a drive within the en-
docrine community to phase out immunoassays where possible [343].
Moreover, the use of high-resolution accurate mass (HRAM) mass
spectrometry coupled to liquid chromatography systems is being ex-
plored as an alternative to traditional MS/MS systems as accurate mass
quantification offers the potential to resolve all steroid metabolites with
the exception of steroid isomers, unless they are separated chromato-
graphically [344].
It should, however, be noted that despite the advantages of mass
spectrometry techniques, these are not without their challenges.
Perhaps the biggest challenge to the endocrine community is the cross
validation of methodologies employed in different laboratories.
Currently differences in sample work-up methodologies and/or in-
strumentation and settings can result in reference ranges that vary
between laboratories. Moving forward methods therefore ideally need
to be validated both internally according to set standards and subse-
quently compared using standardized reference material and quality
controls [345–347].
5.2. Steroid metabolomics
Steroid metabolomics is defined as the combination of steroid me-
tabolome profiling by mass spectrometry with computational machine
learning-based analysis of the mass spectrometry data. Such sophisti-
cated and unbiased computational analysis techniques have shown
potential for assisting and even automating analysis of large or highly
heterogeneous datasets, making it an ideal resource for use in meta-
bolomics. Machine learning involves training a computer program to
recognize patterns within large-scale data - the more data it is exposed
to, the greater the learning capability. This generates a tailor-made
diagnostic algorithm that can be prospectively applied to newly re-
corded steroid data. Interpretable models can help to understand un-
derlying mechanisms, categorize and classify, or even make predictions
based on observed patterns in the data. As an example, this approach
has been used for automating differentiation of adrenocortical carci-
noma (ACC) from benign adrenocortical tumors based on the detection
of a “malignant steroid fingerprint”, a distinct set of urine steroid me-
tabolites characteristically increased in ACC [348]. The principle es-
tablished in this example has opened the door for the application of this
approach to other steroidogenic disorders that create a unique steroid
“fingerprint”.
6. Conclusion
The biosynthesis and metabolism of steroid hormones is complex.
Although the measurement of individual steroids has routinely been
employed for the diagnosis of endocrine conditions for many years,
advances in technology now allow for the high throughput profiling of
comprehensive steroid panels, thereby offering significantly more in-
formation and diagnostic power. Furthermore, the use of unbiased
computational approaches such as machine learning allows for the
development and implementation of steroid metabolomics analysis,
which has the potential to not only improve, accelerate and automate
diagnostics, but also to lead to improvements in treatment monitoring
and prognostic prediction. Nonetheless, a detailed understanding of
steroid biosynthesis and the principles that govern steroid metabolism
and excretion remains fundamental to the accurate interpretation of
metabolomics data as well as the improvement of our understanding of
associated disorders.
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